ElSaygh Jude, Zaher Anas, Nathani Pratiksha, Omballi Mohamed
Internal Medicine, University of Debrecen, Debrecen, HUN.
Internal Medicine, Maharashtra University of Health Sciences, Latur, IND.
Cureus. 2021 Apr 21;13(4):e14618. doi: 10.7759/cureus.14618.
Chronic obstructive pulmonary disease (COPD) has remained a leading cause of death worldwide and is expected to increase its burden on the healthcare system in the coming future. Numerous clinical trials have been conducted over the years and as a result, many drugs became a part of the treatment protocols of COPD. Currently, there are also several drugs under development. This review will help future researchers to grasp salient features of previous studies and use them in their future trials in order to reduce the morbidity and mortality of COPD. Randomized control trials provide strong evidence for any hypothesis in a research study. This review focuses on major COPD trials in the last two decades including TORCH, UPLIFT, POET, WISDOM, and TIOSPIR. It showcases the main clinical question, primary outcome, and result of these five trials.
慢性阻塞性肺疾病（COPD）一直是全球主要的死亡原因之一，预计在未来其对医疗保健系统的负担还会加重。多年来已经进行了大量临床试验，因此，许多药物成为了COPD治疗方案的一部分。目前，也有几种药物正在研发中。本综述将帮助未来的研究人员掌握以往研究的显著特征，并将其应用于未来的试验中，以降低COPD的发病率和死亡率。随机对照试验为研究中的任何假设提供了有力证据。本综述聚焦于过去二十年中的主要COPD试验，包括TORCH、UPLIFT、POET、WISDOM和TIOSPIR。它展示了这五项试验的主要临床问题、主要结局和结果。
